Climb Bio (CLYM)
NASDAQ:CLYM
Top Page
Climb Bio
(NASDAQ:CLYM)
Select Model
Select Model
Rating:52Neutral
Price Target:
$8.50
▼(-3.95% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increased cash burn), partially offset by low leverage and a relatively stronger balance sheet. Technicals suggest a constructive longer-term uptrend but mixed near-term momentum. Corporate events are balanced between supportive clinical/risk-runway updates and a meaningful legal overhang, while valuation is not compelling given loss-driven negative P/E and no dividend support.
Positive Factors
Low leverage / strong balance sheet
Very low debt relative to equity materially reduces refinancing and solvency risk for an early‑stage biotech. This durable financial strength supports continued R&D spending and gives management flexibility on timing and structure of future financings as clinical milestones progress.
Negative Factors
No revenue; widening losses
Absence of product revenue and expanding operating losses mean the company remains fully reliant on external capital. Persistent negative profitability erodes equity over time and sustains execution risk until clinical success or partnering converts R&D into commercial sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt relative to equity materially reduces refinancing and solvency risk for an early‑stage biotech. This durable financial strength supports continued R&D spending and gives management flexibility on timing and structure of future financings as clinical milestones progress.
Read all positive factors
Climb Bio (CLYM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$412.24M
Dividend YieldN/A
Average Volume (3M)496.01K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth64.81%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.26
Shares Outstanding47,767,980
10 Day Avg. Volume431,611
30 Day Avg. Volume496,010
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)0.00
P/FCF Ratio-4.97
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.36K
Enterprise Value/Ebitda-8.91
Forecast
1Y Price Target
$16.80Price Target Upside89.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.13
Revenue Forecast (FY)N/A
Climb Bio Business Overview & Revenue Model
Company Description
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus...
How the Company Makes Money
null...
Climb Bio Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
76
Positive
Cash Flow
29
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -67.79M | -30.36M | -40.27M | -45.13M | -35.67M |
| Net Income | -59.85M | -73.90M | -35.12M | -45.24M | -47.48M |
Balance Sheet | |||||
| Total Assets | 167.74M | 217.19M | 110.47M | 134.99M | 173.24M |
| Cash, Cash Equivalents and Short-Term Investments | 101.08M | 150.92M | 106.80M | 123.57M | 136.48M |
| Total Debt | 541.00K | 532.00K | 349.00K | 480.00K | 0.00 |
| Total Liabilities | 7.27M | 5.31M | 2.87M | 6.28M | 6.04M |
| Stockholders Equity | 160.47M | 211.88M | 107.60M | 128.72M | 167.20M |
Cash Flow | |||||
| Free Cash Flow | -54.54M | -15.56M | -20.60M | -37.37M | -36.07M |
| Operating Cash Flow | -54.36M | -15.56M | -20.60M | -37.37M | -36.07M |
| Investing Cash Flow | 2.83M | -121.09M | 68.98M | 34.44M | -114.97M |
| Financing Cash Flow | -21.00K | 130.73M | 841.00K | 0.00 | 177.23M |
Climb Bio Technical Analysis
Positive
8.85
Price Trends
6.63
Positive
5.07
Positive
3.47
Positive
Market Momentum
0.47
Negative
73.26
Negative
89.57
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLYM, the sentiment is Positive. The current price of 8.85 is above the 20-day moving average (MA) of 7.16, above the 50-day MA of 6.63, and above the 200-day MA of 3.47, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 73.26 is Negative, neither overbought nor oversold. The STOCH value of 89.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLYM.
Climb Bio Risk Analysis
Climb Bio disclosed 70 risk factors in its most recent earnings report. Climb Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Climb Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $367.93M | -6.90 | -23.98% | ― | 946.61% | -11.30% | |
52 Neutral | $412.24M | -4.53 | -33.41% | ― | ― | 64.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $87.07M | -8.98 | -109.73% | ― | ― | 50.39% | |
48 Neutral | $182.47M | -1.21 | -179.42% | ― | ― | 99.21% | |
46 Neutral | $159.35M | 811.87 | -0.04% | ― | -33.41% | 81.19% | |
44 Neutral | $23.24M | -2.09 | 389.21% | ― | ― | -234.46% |
* Healthcare Sector Average
CLYM
Climb Bio
8.85
7.49
550.74%
AGEN
Agenus
4.72
3.03
179.29%
HURA
TuHURA Biosciences
3.15
-0.96
-23.26%
OVID
Ovid Therapeutics
2.96
2.67
934.97%
CGTX
Cognition Therapeutics
0.98
0.60
156.58%
TVGN
Tevogen Bio Holdings
5.98
-46.52
-88.61%
Climb Bio Corporate Events
Business Operations and StrategyExecutive/Board Changes
Climb Bio Consolidates Financial Leadership After SVP Departure
Neutral
Apr 3, 2026
On April 1, 2026, Climb Bio, Inc. and Senior Vice President, Finance and principal accounting officer Cindy Driscoll mutually agreed that she would depart the company, with her separation taking effect on April 30, 2026. In connection with her dep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.